AEZS News 1.19 08/14/2014 04:28:00 Aeterna Zentaris (AEZS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 1.19 $AEZS

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
PR Newswire - Thu Aug 07, 3:30PM CDT
All amounts are in US dollars

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
CNW Group - Wed Aug 06, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Canaccord Genuity 34th Annual Global Growth Conference on Wednesday, August 13, 2014, at 1pm (Eastern), in the Melbourne Room of the Intercontinental Hotel in Boston.

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
PR Newswire - Tue Aug 05, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced a strategic co-promotion services agreement with ASCEND Therapeutics® US, LLC, ("ASCEND" . Under the terms of the agreement, expected to start in the fourth quarter of 2014, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel® a non-patch transdermal U.S. Food & Drug Administration ("FDA" approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency ("AGHD" , for which a New Drug Application ("NDA" is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA" date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.

Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:

Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.

Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada.

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 77

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 119

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 172

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 53

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 102

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 9

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 226

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 23

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading

Top 5 Most Recently Viewed Articles

RTX and Cebu Pacific Forge Strategic Engine Maintenance Alliance

Updated Category News Views 201

Strategic Partnership Between RTX and Cebu Pacific In an exciting development for aviation partnerships, Pratt & Whitney, an RTX (NYSE: RTX) business, and Cebu Pacific have entered into a comprehensive long-term agreement aimed at maintaining the efficiency and reliability of Cebu Pacific’s GTF engine fleet. This strategic collaboration underlines the critical role of...

Continue Reading
Hellenic Music Ensemble Embarks on North American Tour

Updated Category News Views 172

The Hellenic Music Ensemble's Exciting North American Tour The Hellenic Music Ensemble is set to take North American audiences on a mesmerizing journey through Greece's rich musical heritage in 2026. Led by the talented Natassa Bofiliou and Giannis Haroulis, alongside special guest star Judy Kuhn, this tour promises to be a landmark event. Celebrating Greek Composers This...

Continue Reading
University of Maryland's Groundbreaking Fundraising Initiative

Updated Category News Views 258

University of Maryland Launches Its Largest Fundraising Campaign The University of Maryland proudly announces its most ambitious fundraising endeavor to date, aimed at elevating education and research. Titled Forward: The University of Maryland Campaign for the Fearless, this initiative seeks to raise an impressive $2.5 billion. With the goal of advancing the university's...

Continue Reading
New Insights on Dowlais Group Plc's Recent Activity

Updated Category News Views 203

Understanding Recent Trading Disclosures by Dowlais Group Plc As the financial landscape continuously evolves, public disclosures play a crucial role in ensuring transparency, trust, and regulatory compliance. Dowlais Group Plc, a notable player in the market, recently had transaction disclosures that are vital for investors and stakeholders alike. The company's exemplary...

Continue Reading
Stock Market Updates: Gains, Losses, and Oil Inventory Trends

Updated Category News Views 142

Recent U.S. Stock Market Movements As the trading day nears its end, U.S. stock indices show promising trends, with the S&P 500 making notable gains recently. This uptrend reflects a resilient market which continues to respond positively amidst economic fluctuations. Key Market Index Performances On Thursday, the Dow Jones Industrial Average climbed by 0.24%, reaching...

Continue Reading